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Zhengyuan Xia1,3,4* and Michael G Irwin1,3Abstract
Background: Large body of evidences accumulated in clinical and epidemiological studies indicate that hearts of
diabetic subjects are more sensitive to ischemia reperfusion injury (IRI), which results in a higher rate of mortality at
post-operation than that of non-diabetes. However, experimental results are equivocal and point to either increased
or decreased susceptibility of the diabetic hearts to IRI, especially at the early stage of the disease. The present
study was designed to test the hypothesis that the duration/severity of the indexed ischemia is a major
determinant of the vulnerability to myocardial IRI at early stage of diabetes.
Methods: Four weeks streptozotocin (STZ)-induced diabetic (D) and non-diabetic (C) Sprague–Dawley rats were
randomly assigned to receive 30 or 45 min of left anterior descending artery ligation followed by 2 or 3 hours of
reperfusion, respectively. Cardiac function was recorded by using Pressure-Volume (PV) conduction system.
Myocardial infarct size was determined with triphenyltetrazolium chloride staining. Plasma Creatine kinase-MB
(CK-MB), Lactate dehydrogenase (LDH) release, myocardial nitric oxide(NO) content and nitrotyrosine formation,
15-F2t-Isoprostane and plasma superoxide dismutase (SOD) were measured with colorimetric assays. Cardiomyocyte
apoptosis was assessed by TUNEL staining. Myocardial TNFα, Caspase-3, STAT3, Akt, and GSK-3β were determined
by Western blotting.
Results: Prolongation of ischemia but not reperfusion from 30 min to 45 min significantly increased infarct size
in D compared to C rats (P < 0.05), accompanied with significantly increased plasma CK-MB (P < 0.05). Prolongation
of the duration of either ischemia or reperfusion significantly increased plasma LDH release and myocardial
15-F2t-Isoprostane and reduced plasma SOD activity, with concomitant reduction of myocardial NO and increase
of nitrotyrosine formation in D relative to C (P < 0.05). Prolongation of ischemia and reperfusion significantly
reduced left ventricular ejection fraction and increased the peak rate of pressure, accompanied with increased end
systolic pressure in D relative to C rats (P < 0.05) but reduced phosphorylations of myocardial STAT3 at site Ser727
and Akt at site Ser473 as well as GSK-3β at Ser 9 (P < 0.05).
Conclusions: Diabetic hearts, even at early stage of the disease are more sensitive to IRI, and this increased severity
of post-ischemic myocardial injury depends more on the duration of ischemia than that of reperfusion.
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Despite of the current optimal therapy, the mortality
and morbidityof patients with ischemic heart disease
(IHD) remains high [1], particularly in patients with
diabetes mellitus (DM) [2]. Myocardial infarct size is a
major determinant of prognosis in patients with IHD,
and development of a novel strategy to limit infarction is
of great clinical importance. Clinical studies showed that
DM increased the susceptibility of myocardium to
ischemia-reperfusion injury (IRI) [3,4]. Larger infarct
size, higher rates of new onset of severe congestive heart
failure after reperfusion therapy were observed in DM
patients than in non-DM patients [4]. In consistent with
the change in myocardial vulnerability to infarction, pa-
tients with diabetes exhibit worse recovery after acute
myocardial infarction (AMI) evidenced as worse short-
and long-term prognosis after AMI [5,6]. Of particular
relevance, studies showed that cardiovascular event risk
in DM patients without prior myocardial infarction was
comparable to the risk in non-diabetic patients with
prior myocardial infarction [2]. Diabetes not only ren-
ders the heart more vulnerable to ischemic insult but
also abolishes or compromises the effectiveness of cardio-
protective interventions such as ischemic pre- or post-
conditioning [7,8]. These available clinical evidences [7,8]
strongly support the notion that DM increases the sensi-
tivity of the heart to IRI.
Despite the overwhelming clinical data indicating that
the diabetic heart is more sensitive to IRI, results from
experimental diabetic animal models studies were
contradictory. Some studies have shown that the diabetic
heart is less sensitive to ischemic injury [7,9,10], while
others have indicated that the diabetic heart is more
sensitive [8,11,12]. Others found no differences in the
vulnerability of the diabetic heart to IRI relative to non-
diabetes [13,14]. Several factors have been proposed to
explain the discrepancy in the effects of DM on the
vulnerability to myocardial IRI in animal studies, which
includes the duration and the severity of the diabetic
state, experimental protocols (e.g. degree of ischemia
and reperfusion, type of animal species), and metabolic
profiles after diabetic induction. Among them, inconsist-
ency of experimental protocols has been suggested to be
the main cause. Marfella et. al [15] reported that myocar-
dial infarct size after 25 minutes(min) ischemia followed
by 2 hours reperfusion was larger in streptozotocin
(STZ)-induced diabetic rats as early as 8 days after the
induction of diabetes than that in non-diabetic rats.
However, reduction of infarct size was observed in
2 weeks STZ-induced diabetic rats with 30 min ische-
mia/2 hours reperfusion [16]. Due to the fact that dif-
ferent protocols and animal species were employed in
different studies, results gained from different studies
regarding the vulnerability of the diabetic heart at theearly stage of the disease, are not comparable, as such it
remains unclear whether or not the diabetic hearts at
the early stage of diabetes are more sensitive to IRI.
Therefore, a systemic study by applying multiple dura-
tions of ischemia and/or reperfusion at the same diabetic
model is needed to address this question.
Excess oxidative stress caused by the burst of reactive
oxygen species (ROS) in the presence of inadequate anti-
oxidant defense, has been considered as a potential
mechanism governing the increased sensitivity of the
diabetic heart to IRI [17]. Under physiological condition,
in which ROS are in low concentrations, it serves as
signaling molecules which is beneficial to the heart [18].
However, under pathological (including diabetes) con-
dition, ROS elicits harmful effects when produced in
excess [19]. ROS production is increased both during
ischemia and within a few minutes of reperfusion, which
leads to and exacerbates myocardial IRI.
To our knowledge, there is no systematic study to
address the impact of durations of ischemia and/or
reperfusion on the sensitivity of diabetic heart to IRI,
especially at the early stage of the disease. Therefore, the
aims of this study were to employ different durations of
myocardial ischemia and reperfusion in STZ-induced
diabetic rats at the early stage of the disease (4 weeks) to
address whether or not diabetic heart is more sensitivity
to IRI.
Methods
Induction of diabetes
Male Sprague-Dawley rats (250 ± 10 g, 6–8 weeks)
obtained from the Laboratory Animal Service Center
(the University of Hong Kong) were used in this study.
All rats were housed and given free access to standard
rat chow and water in accordance with the principles of
Animal Care of the University of Hong Kong. The
experimental protocol used in this study was approved
by the Committee on the Use of Live Animals in Teach-
ing and Research (CULATR). Diabetes was induced by a
single tail vein injection of STZ at the dose of 65 mg/kg
bodyweight (Sigma-Aldrich, St. Louis, MO) in 0.1 M
citrate buffer (pH 4.5) or citrate buffer alone as control
under anesthesia with a combination of ketamine
67.7 mg/kg bodyweight and xylazine 6.77 mg/kg
bodyweight. After 72 hours injection, blood glucose was
measured using a One Touch Ultra Glucose meter (Life
Scan Inc. USA) and rats with blood glucose levels over
15 mM were considered diabetes.
Measurements of general characteristics
During treatment period, water intake was assessed
daily; food consumption and body weight were moni-
tored weekly. Blood glucose levels (mM) were measured
once a week by using a One Touch Ultra Glucose Meter
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onset of diabetes at the absent or present of myocardial
ischemia reperfusion), rats were weighed and then
euthanized following anaesthesia with an intraperitoneal
injection of pentobarbital sodium (65 mg/kg). Blood
samples were obtained from carotid artery after an over-
night fast of 8–10 h, and plasma was extracted and
stored at −80°C until analyzed. Serum Total Cholesterol
(TC) and Triglyceride (TG) were determined using com-
mercially available kits (Stanbio laboratory, TX, USA),
respectively.
Experimental protocol
After completion of instrumentation and surgery, rats
were allowed a 15 min equilibration period. Diabetic (D)
and non-diabetic (C) rats were randomly assigned to
receive 30 or 45 min of left anterior descending (LAD)
artery occlusion followed by either 120 or 180 min of
reperfusion, respectively.
Myocardial ischemia reperfusion injury in vivo
Rats were anesthetized by intraperitoneal injection of
sodium pentobarbital (65 mg/kg) and the trachea was
cannulated with a polyethylene tube connected to a
rodent respirator (Harvard Apparatus, Holliston, MA)
with a tidal volume of 1.0 mL/100 mg body weight
(60 breaths/min) [20]. Then left thoracotomy was
performed between the fourth and fifth ribs. The peri-
cardial tissue was removed under a microscope and the
LAD artery was ligated with 6–0 silk suture using a
snare occluder [21]. The rats were then subjected to
30 min or 45 min of LAD ligation followed by 120 min
or 180 min of reperfusion.
Measurement of left ventricular function
The global cardiac functions under the load dependent
and independent conditions were monitored by using a
Pressure-Volume (PV) conductance catheter (AD Instru-
ments, Colorado Springs, CO, USA) placed into the left
ventricle through right carotid artery and connected to a
computer equiped with an Advantage PV control box
software (AD Instruments, Colorado Springs, CO, USA).
Briefly, rats were anesthetized with an intraperitoneal
injection of sodium pentobarbital (65 mg/kg) and venti-
lated with room air mixed with pure oxygen using a
rodent ventilator. A Millar ultra-miniature PV catheter
was advanced into the left ventricle (LV) of rat beating
heart. The hemodynamic parameters in each rat were
measured in the chest opened rats and the LAD was
occluded after stabilization for 10 min. At baseline and
at the end of reperfusion, the cardiac functions were
recorded and compared between the C and D rats. The
cardiac functional parameters recorded include heart
rate (HR); left ventricular end-systolic pressure (LVESP);left ventricular end-diastolic pressure (LVEDP); stroke
volume (SV); left ventricular ejection fraction (LVEF);
stroke work (SW). The load-independent contractility
parameters including the peak rate of pressure increase
(dP/dt max); arterial elastance (Ea = LVESP/SV); the peak
rate of pressure decrease (dP/dt min); the relaxation time
constant calculated by Weiss method (Tau) were analyzed
using Labchart 7 software (AD Instruments, Colorado
Springs, CO, USA).
Determination of myocardial infarct size
At the end of the experiment, myocardial infarct size
was measured using TTC (1% 2,3,5-triphenyltetrazolium
chloride) staining as we described [21]. Briefly, the LAD
was re-occluded and cannulated just distal to the occlu-
sion site. Ten milliliters of saline and 10 mL of patent
blue dye were injected at equal pressure into the LAD
and left atrium, respectively, to delineate the anatomic
area at risk (AAR) subjected to prolonged occlusion and
reperfusion and the non-ischemic normal zone. The
heart was immediately fibrillated, removed, and sliced
into serial transverse sections 6 to 7 mm in width. The
unstained AAR was separated from the blue stained
normal area, and the two regions were incubated at 37°C
for 20 to 30 min in 1% TTC in 0.1 mol/L phosphate
buffer adjusted to pH 7.4, and photographed with a digital
camera. TTC stains non-infarcted myocardium a brick
red color because of the presence of a formalin precipitate,
resulting from reduction of TTC by dehydrogenase
enzymes present in viable tissue. Infarcted myocardium
remains unstained. Infarcted and non-infarcted myo-
cardium within the AAR were digitally measured using an
image analysis software (ImageJ, version 1.47, National
Institutes of Health, Bethesda, MD). Infarct size (IS) was
expressed as a percentage of the AAR.
Measurements of plasma Creatine kinase-MB (CK-MB) and
Lactate dehydrogenase (LDH) levels
Plasma CK-MB levels were determined using a commer-
cially available rat ELISA kit (R&D Systems, Minneapolis,
MN). Plasma LDH levels were measured using a commer-
cially available kit (Roche, Germany).
Determination of plasma free 15-F2t-Isoprostane
(15-F2t-IsoP) and superoxide dismutase (SOD) activity
15-F2t-IsoP, a specific marker of oxidative stress in vivo,
was measured using an enzyme immunoassay kit (Cayman
Chemical, MI, USA) as described previously [21]. Plasma
samples homogenates in PBS were purified using Affinity
Column and Affinity Sorbent (Cayman Chemical, MI,
USA). The absorbance from the enzymatic reaction was
detected at 412 nm. The plasma 15-F2t-isoP levels are
expressed as pg/ml. The total SOD activity in plasma was
Table 1 General characteristics before myocardial
ischemia reperfusion
Parameters C D
Water intake (ml/kg/day) 134.7 ± 8.1 725.3 ± 9.3*
Food consumption (g/kg/day) 61.9 ± 3.1 164.7 ± 11.2*
Body weight (g) 478.2 ± 10.3 351.4 ± 8.9*
Plasma glucose (mM) 7.1 ± 0.5 28.9 ± 1.2*
Heart/body weight ratio (g/kg) 2.6 ± 0.1 3.0 ± 0.1*
Triglycerides (mg/dL) 126.09 ± 11.4 220.95 ± 9.7*
Cholesterol (mg/dL) 75.66 ± 6.7 89.70 ± 9.1
All values are expressed as mean ± S.E.M. n = 7 per group. Water intake and
food consumption were the average value of four weeks. Body weight, Heart/
Body weight ratio, plasma glucose, triglycerides and cholesterol were
measured at 4-week after STZ injection in these two groups. All of the indices
were measured between groups before inducing myocardial ischemia
reperfusion. *P < 0.05 vs. C.
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according to the manufacturer’s recommendations.
Determination of myocardial levels of nitric oxide and
nitrotyrosine
Concentrations of nitrites (NO2−) and nitrates (NO3−), the
stable end products of nitric oxide (NO), were determined
at the end of reperfusion in the ventricular tissue by a NO
colorimetric assay kit (BioVision, Inc. California). The
values of cardiac NO production were expressed as the
total nitrate and nitrite levels. Cardiac nitrotyrosine, a
footprint of peroxynitrite was measured with chemi-
luminescence detection (Millipore, Billerica, MA, USA)
according to the manufactory’s instruction.
Protein extraction and immunoblotting
Heart tissue were homogenized using lysis buffer
[(20 mmol/L Tris–HCl pH = 7.5, 50 mmol/L 2-
mercaptoethanol, 5 mmol/L EGTA, 2 mmol/L EDTA,
1% NP40, 0.1% sodium dodecyl sulfonate (SDS), 0.5%
deoxycholic acid, 10 mmol/L NaF, 1 mmol/L PMSF,
25 mg/mL leupeptin, 2 mg/mL aprotinin)], sonicated
and centrifuged at 12 000 g for 20 min at 4°C. Protein
concentrations were determined using the Bradford assay
(Bio-Rad, USA). Samples containing equal amounts of
proteins were separated on a 10% SDS-polyacrylamide gel
and then the proteins were transferred to PVDF mem-
brane. Membranes were blocked with 5% non-fat milk in
Tris-Buffered Saline (TBS)-Tween and were incubated with
primary antibodies overnight at 4°C at the following dilu-
tions: Akt, signal transducer and activator of transcription
3 (STAT3), glycogen synthase kinase-3 beta (GSK-3β) and
GAPDH (Cell Signaling Technology, Beverly, MA) 1:1000;
phosphor-STAT3 (Ser 727), phosphor-Akt (Ser 473) and
phosphor-GSK-3β (Ser 9) (Cell Signaling Technology,
Beverly, MA) 1:500. After washing with phosphate buffered
saline-tween (PBST), membrane strips were washed and
incubated with horseradish peroxidase (HRP)-conjugated
anti-rabbit and detected by enzymatic chemiluminescence.
Immunohistochemistry (TUNEL)
Paraffin-embedded left ventricular tissue blocks were
sectioned at 5 mm. Then, the sections were dewaxed
and rehydrated. Slides were incubated in 3% hydrogen
peroxide/methanol. Antigen retrieval was performed by
heating in 10 mM sodium citrate buffer for 10 min.
Sections were incubated in anti-collagen I antibody
(abcam, USA) at 1:50 dilution for 12 h at 4°C. 3,3′-
Diaminobenzidine Substrate Chromogen System (Dako,
S1699) was employed in the detection procedure. Subse-
quently, the sections were counterstained with nuclear fast
red for 3 min. Finally, the sections were dehydrated in
ethanol, cleared in xylene, mounted and observed in a
light microscope. The sections were observed in the lightmicroscope by an investigator who was initially blinded to
treatment groups, and five randomly selected fields of
each slide were semi-quantified and averaged using the
software Image J 1.42 (National Institutes of Health)
according to its instructions.
Statistical analysis
All the values are expressed as mean ± standard error
of the mean (S.E.M). One-way analysis of variance
(ANOVA) was used for statistical analyses (GraphPad
Prism, USA) of data obtained within the same group
of rats and between groups of rats, respectively,
followed by Tukey’s test for multiple comparisons of
group means. P < 0.05 was considered statistically
significant.
Results
General characteristics at termination
STZ-induced diabetic rats displayed hyperglycemia,
hyperlipidemia, polydipsia and polyphagia evidenced as
significantly increased plasma glucose, triglycerides, cho-
lesterol, water intake and food consumption, compared
with age-matched controls (all P < 0.05, Table 1). The
body weight in the diabetic group was lower than that in
the control group (P < 0.05), while the heart/body weight
ratio in the diabetic group were higher than that in the
control group (P < 0.05).
Infarct size and myocardial injury after IR
As shown in Figure 1, myocardial infarct size (IS) was
bigger in D than that in C but could not reach statistical
significance when the rats were subjected to 30 min of
LAD occlusion followed by either 2 or 3 hours. How-
ever, when the duration of LAD occlusion was extended
to 45 min followed by either 2 or 3 hours, significant
bigger infarct size was observed in D relative to C rats
(Figure 1A) (P < 0.05). Similar to our previous report
Figure 1 Myocardial infarct size and cellular injury after myocardial ischemia reperfusion in control and diabetic rats. A. Percentage
of infarct size (IS) expressed as a percentage of the area at risk (AAR), B. Plasma CK-MB secretion assessed by ELISA kit, C. Plasma lactate
dehydrogenase (LDH) leakage, D. Protein expression of cardiac Tumor necrosis factor α(TNF α). Data are expressed as mean ± SEM
(n = 7 per group). *P < 0.05, **P < 0.01 in C vs. D.
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reperfusion, the myocardial IS between control and
diabetic rats did not reach statistical significance, while
the release of plasma CK-MB was significantly increased
in D relative to C after reperfusion (Figure 1B) (P < 0.05),
which was consistent with a significant increase of
plasma LDH (P < 0.05) and cardiac TNFα protein ex-
pression (P < 0.05) after 30 min LAD occlusion with 2
or 3 hours reperfusion (Figure 1C and D). Diabetic
rats subjected to 45 min LAD occlusion with either 2
or 3 hours reperfusion resulted in a significant in-
crease in IS when compared to that of C rats (Figure 1A).
Of note, when we extended the duration of LAD to
60 min, we observed that the majority of the rats in
both the C and the D groups could not survive (data
not shown). As shown in Figure 2A, after IR, apoptotic
myocytes was significantly increased in diabetic rats
evidenced as larger number of TUNEL-staining positive
cells compared with controls (Figure 2A) (P < 0.05),
which was coincident with a significantly increase of
cardiac caspase-3 protein expression after IR (Figure 2B)
(P < 0.05).
Left ventricular functions
Before inducing IR (baseline) and at the end of IRI, cardiac
function was determined by using a pressure volume
conduction system. As shown in Figure 3, STZ-induced
diabetes displayed poor cardiac function evidenced as
significantly lower LVEF, SV, dP/dt max, and dP/dt mincompared to controls (Figure 3B, D, and E) (P < 0.01 vs. C).
Diabetes rats displayed a significant decrease in HR before
(baseline) and after IRI (Figure 3A) (P < 0.01 vs. C). LVEF, a
surrogate marker of heart failure status was significantly
reduced in diabetic rats relative to control rats when the
rats were subjected to 30 min ischemia followed by 3 hours
but not by 2 hours reperfusion. When the duration of
ischemia was 45 min, LVEF in the diabetic group was con-
stantly lower than that in the control group following
either 2 or 3 hours of reperfusion (Figure 3B) (P < 0.05 vs.
C). At baseline and the end of IRI, the important contract-
ile function index dP/dtmax and dP/dtmin were significantly
decreased in diabetic rats relative to controls (Figure 3D
and E) (P < 0.01 vs. C), despite that no significant difference
was observed in LVEDP (Figure 3F). Significant decrease in
LVESP was only observed in diabetic rats subjected to
45 min LAD occlusion followed by 3 hours reperfusion
(Figure 3G) (P < 0.05 vs. C). The value of Ea did not signifi-
cantly differ between diabetic and control groups at base-
line, but it was significantly reduced in diabetic rats relative
to controls when the rats were subjected to either 30 min
or 45 min of reperfusion followed by 2 or 3 hours of reper-
fusion (Figure 3H) (P < 0.01 vs. C). Tau Weiss was signifi-
cantly increased in diabetic rats as compared to control
rats (Figure 3I) (P < 0.01).
Oxidative stress and antioxidant status after inducing IR
As shown in Figure 4, after IR, plasma 15-F2t-IsoP
was elevated in both the control and the diabetic rats
Figure 2 Myocardial cell apoptosis assessed by TUNEL staining and cardiac caspase-3 protein expression before and after myocardial
ischemia reperfusion. A. Myocardial cell apoptosis assessed by TUNEL, TUNEL positive cells were stained brown as indicated by arrow, B.
Cardiac caspase-3 protein expression. Data are expressed as mean ± SEM (n = 7 per group). *P < 0.05, **P < 0.01 vs. C.
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(P < 0.05) (Figure 4A and B). After 30 min LAD
occlusion with 2 hours reperfusion, plasma 15-F2t-
IsoP in diabetic group was relatively higher than that
in the control group but the difference did not reach
statistical significance, while when the duration of reperfu-
sion was extended to 3 hours or the duration of LAD
occlusion extended to 45 min, plasma 15-F2t-IsoP was sig-
nificantly increased in diabetic compared with control
group (Figure 4A) (P < 0.05). After 4 weeks of diabetes,
baseline (before inducing IR) myocardial nitric oxide pro-
duction in diabetic rats was lower than that in control rats
(P < 0.05). After 30 min LAD occlusion/2 hours reperfu-
sion or 45 min LAD occlusion followed by either 2 hours
or 3 hours reperfusion, myocardial nitric oxide was sig-
nificantly increased in diabetic rats relative to controls
(Figure 4C) (P < 0.05), accompanied with a significant
increase myocardial nitrotyrosine formation (Figure 4D)
(P < 0.05).
Myocardial STAT3, Akt, and GSK-3β expression after IR
Studies from ours [12,21] and others [22] have shown that
phosphoinositide 3-kinase (PI3K)/Akt and Janus kinase 2
(Jak2)/STAT3 signaling pathways may be involved inantioxidant-mediated NO production and subsequently
contribute to myocardial protection against ischemia
reperfusion injury. As shown in Figure 5B, before and
after inducing IR, phosphorylation of myocardial Akt at
Site Ser473 was significantly reduced in diabetic rats rela-
tive to controls (P < 0.05) (Figure 5B), and similarly, its
downstream molecule, glycogen synthase kinase-3β (GSK-
3β), was significantly reduced in diabetic rats compared to
controls both before and after inducing IR as evidenced
by reduced phosphorylation at Ser9 (Figure 5C) (P < 0.05).
As we previously reported [21], STAT3 phosphorylation
contributes to myocardial eNOS activation and NO
production, therefore, we investigated the change in myo-
cardial protein levels of STAT3. As showed in Figure 5A,
a significant reduction of p-STAT3 was observed in
diabetic rats compared to controls both before and after
inducing IR (Figure 5A) (P < 0.05).
Discussion
In this study, using in vivo ischemia reperfusion model
incorperating with the application of different durations
of ischemia and reperfusion in the same disease model,
we demonstrated that the diabetic hearts, even at the
early stage of the disease, are more sensitive to IRI than
Figure 4 Biochemical assessment before and after ischemia reperfusion in control and diabetic rats. A. Myocardial levels of 15-F2t-
Isoprostane, B. Plasma levels of SOD, C. Cardiac NO production, D. Myocardial nitrotyrosine. Data are expressed as mean ± SEM (n = 7 per group).
*P < 0.05, **P < 0.01 vs. C.
Figure 3 Left ventricular function before and after ischemia reperfusion in control and diabetic rats. A. HR: heart rate, B. LVEF: left
ventricular ejection fraction, C. SV: stroke volume, D. dP/dt max: load-independent contractility parameters including the peak rate of pressure
increase, E. dP/dt min: the peak rate of pressure decrease, F. LVEDP: left ventricular end-diastolic pressure, G. LVESP: left ventricular end-systolic
pressure, H. Ea: arterial elastance (Ea = LVESP/SV), I. Tau: relaxation time constant calculated by Weiss method. Data are expressed as mean ± SEM
(n = 7 per group). *P < 0.05, **P < 0.01 vs. C.
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Figure 5 Myocardial STAT3, Akt and GSK-3β protein expression and their phosphorylation status before and after ischemia
reperfusion in control and diabetic rats. A. Total and phosphorylation (Ser727) of STAT3, B. Total and phosphorylation (Ser473) of Akt, C. Total
and phosphorylation (Ser9) of GSK-3β, D. Representative Western blots. Mean band density was normalized relative to GAPDH. Data are expressed
as mean ± SEM (n = 7 per group), *P < 0.05, **P < 0.01 vs. C.
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showed that the severity of the post-ischemic myocardial
injury of the diabetic hearts depended more on the
duration of ischemia than that of reperfusion. The sever-
ity of oxidative stress and reduction of endogenous anti-
oxidant capacity and the impairment of protective
signaling pathway related to the activation of STAT3 and
Akt are likely the major mechanisms responsible for the
increased post-ischemic myocardial injury in diabetes
after prolonged ischemic insult. To our knowledge, this
is the first systematic study to investigate the mutual
impact of duration of ischemia and reperfusion on myo-
cardial tolerance to IRI in diabetes, particularly, in the
early phase of diabetes. Our findings may help to resolve
the discrepancy regarding whether or not hearts from
diabetes at the early stage of the disease are less resistant
to ischemic insult.
Although clinical studies have convincingly demon-
strated that the diabetic heart is more vulnerable to IRI,
results from experimental studies are still inconsistent,
especially at the early stage of the disease. Smaller infarct
size was observed after 30 min ischemia in diabetic rat
hearts at 1 week after STZ injection than in controls,
but this infarct size limiting effect was disappeared
8 weeks later [9]. Similarly, Ma et al. [10] reported that
the diabetic hearts were more sensitive to IRI only at the
late phase of the diabetes. However, enlargement of
infarct size was observed as early as 8 days in STZ-
induced diabetes [15]. Thus, despite of the consensus
that hearts from chronic diabetic subjects are more sen-
sitive to IRI than hearts from controls, results obtainedfrom studies conducted at the early stage of diabetes are
mostly inconsistent. Of note, there are numerous differ-
ences in experimental preparations and protocols in the
reported studies, and a single factor cannot entirely
explain the discrepancy in the effects of diabetes on the
sensitivity of the heart to ischemia reperfusion injury.
Therefore, in the present study, we applied different dur-
ation of ischemia and reperfusion in the same diabetic
model to examine whether or not the diabetic heart is
more vulnerable to IRI at its early stage. Studies in non-
diabetes subjects have shown that a sigmoidal relation-
ship exists between myocardial infarct size and duration
of ischemia, where, 20 min of ischemia only induced
extremely small infarct size [23,24], and significant im-
pact of the duration of reperfusion only observed when
ischemia time was shorter than 60 min in non-diabetes
[24]. However, our previous study showed that myo-
cardial infarct size in rats at 4 weeks of STZ-induced
diabetes did not significantly differ from that in the non-
diabetic rats when the rats were subjected to 30 min
ischemia followed by 2 hours of reperfusion [21]. There-
fore, in the current study we applied different durations
of ischemia (30 min and 45 min) followed by either
2 hours or longer duration (3 hours) of reperfusion to
see whether or not diabetic rats were more sensitive to
IRI than non-diabetc rats. We found that enlargement of
infarct size was only detectable when the diabetic rats
were subjected to a longer enough (45 min) duration of
ischemia with either 2 or 3 hours reperfusion, wherever
the release of plasma CK-MB and plasma LDH were
significantly increased in diabetic rats relative to controls
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reperfusion. These indicate that myocardial cellular
injury is more severe in diabetic than that in the control
rats during reperfusion, despite that significant dif-
ference of infarct size was only observed when rats
subjected to 45 min of ischemia with 2 or 3 hours reper-
fusion. Infarct size is considered as the gold standard in
assessing the severity of heart damage after ischemia
reperfusion, while CK-MB is regarded as the diagnostic
hallmark for assessing post-ischemic myocardial infarc-
tion in patients after acute myocardial ischemia [25,26].
Reports from different studies showed that these two
reliable parameters, infarct size and CK-MB, not always
reach their peak values at the same time. In patients
with acute myocardial ischemia, plasma CK-MB reaches
its peak level at about ten hours after ischemia and pre-
dicts well with myocardial infarct size which reaches its
peak level at five to seven days after reperfusion with
thrombolytic therapy [26]. Similar findings have also
been reported in a rat model, which showed that the
increase in post-ischemic CK-MB peaked minutes after
reperfusion while significant myocardial infarct size did
not become apparent until after one hour of reperfusion
[27]. In the present study, significant higher post-
reperfusion CK-MB levels and LDH levels (a marker of
cell necrosis) in diabetic rats correlated with more
severely impaired post-reperfusion left ventricular func-
tion and increased numbers of apoptotic cardiomyocytes
as compared to controls. In the current study, significant
difference in post-reperfusion infarct size between
diabetic and control rats were only detected when the
rats were subjected to 45 minutes of ischemia with 2 or
3 hours of reperfusion but not after 30 min of ischemia
followed by 2 hours reperfusion despite of the significant
increase in CK-MB level and LDH levels. This indicates
that the reperfusion time of 180 minutes may not be
long enough to catch significant increase in infarct size
in the diabetic group when the duration of ischemia was
set at 30 min. In other words, enlargement of infarct size
depended more on the duration of ischemia but not (or
to a less degree) on that of reperfusion. In line with our
present results, studies in dogs [28] and patients [29]
showed that myocardial necrosis is time dependent and
ischemia time serves as a determinant of infarct size and
subsequent left ventricular dysfunction in individual
patients with myocardial infarction. Significantly higher
levels of CK-MB and LDH as well as more severe
impairment in post-ischemic left ventricular function
and increased apoptotic cardiomyocytes in the diabetic
rats as shown in the present study indicate that myo-
cardial injury is more severe in diabetic than in control
rats, even at the early stage of the disease (4 weeks of
diabetes). More importantly, results from current study
also suggest that inconsistence of experimental protocolsmay be responsible for the discrepancy of the previously
reported results.
Larger amount of studies support the concept that
increased oxidative stress, such as a burst of reactive
oxygen species production and reduction of antioxidant
capacity contribute to myocardial tissue injury secondary
to ischemia and reperfusion [30], especially in diabetic
heart, in which hyperglycemia enhances myocardial oxi-
dative stress and subsequently aggravates diabetic heart
damage to IRI [31]. It has been widely accepted that
prolongation of ischemia would dramatically increase
myocardial pro-inflammatory cytokine TNFα production
[32], which will subsequently increase the formation of
nitrotyrosine and concomitantly reduce the activities of
antioxidant enzymes, leading to a burst of ROS pro-
duction which is detrimental to the myocardium [33].
As shown in the present study, STZ-induced diabetic
rats exhibited increased myocardial oxidative stress
manifested as increased myocardial 15-F2t-Isoprostane
production and reduced plasma SOD activity, which was
accompanied with increased myocardial TNFα protein
expression, reduced myocardial nitric oxide production
and increased myocardial nitrotyrosine formation. It has
been documented that during ischemia and reperfusion,
especially in the early few minutes of reperfusion,
increased myocardial oxidative stress, such as augment
of 15-F2t-IsoP production and reduction of SOD activity
contribute to myocardial injury [27]. Similarly, in the
present study, after ischemia reperfusion, diabetic rats
displayed more severe oxidative stress, shown as signifi-
cantly increased myocardial 15-F2t-IsoP production and
reduction of plasma SOD activity relative to control. Of
note, progressively significant increase of myocardial 15-
F2t-IsoP production was observed when diabetic rats
subjected to longer duration (from 30 min to 45 min) of
ischemia but not that of reperfusion, which suggests that
15-F2t-IsoP production occurs mainly at the time of
ischemia or in the early minutes of reperfusion and
maintains at certain level when reperfusion sustained.
This is consistent with our previous report showing that
15-F2t-IsoP increased at the time of reperfusion and
progressively reduced during reperfusion and that 15-F2t-
IsoP per se can exacerbate myocardial IRI in isolated rat
hearts [27]. We observed a remarkable compensatory
increase of plasma SOD activity in diabetes when reperfu-
sion last for a longer time (from 2 hours to 3 hours),
which is similar to our previous study showing that in
9 weeks of STZ-induced diabetic rats, a compensatory
increase in myocardial total antioxidant capacity occurred
as a consequence of the increase of cytosolic Cu/Zn-SOD,
but yet it was not sufficient to prevent hyperglycemia-
induced oxidative stress [34]. It should be noted that
oxidative stress represents a major cause of reduced
myocardial nitric oxide (NO) availability. NO, produced
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strated to play an important role in contributing to cardio-
vascular homeostasis and enhanced bioavailability of
endogenous NO has been shown to protect the heart from
myocardial IRI [35]. Physiologically, NO is mostly pro-
duced from endothelial NO-synthases (eNOS), which
exhibits beneficial effects to the heart. Under pathological
condition, including diabetes and ischemia stimuli, indu-
cible NOS (iNOS) is excessively expressed and produces
large amount of NO, which in the concomitant presence
of excessive superoxide formation results in the formation
of peroxynitrite, leading to exacerbated myocardial injury
at the setting of ischemia reperfusion [30]. In the present
study, reduced myocardial NO and increased nitrotyrosine
were observed in diabetic rats compared to control
both before and after ischemia reperfusion, which sug-
gest that an reduction of NO bioavailability was existed
in diabetic heart.
Two important signaling pathways namely, the reper-
fusion injury signaling kinase (RISK) pathway including
PI3K/Akt signaling cascade and the protective survivor
activating factor enhancement (SAFE) pathway including
Jak2/STAT3 signaling cascade play key roles in enhan-
cing myocardial NO bioavailability. Our previous reports
[12,21] showed that myocardial phosphorylation of Akt
and STAT3 were decreased significantly in diabetic rats
at the early stage of the disease followed by decreased
eNOS activation, which subsequently reduced NO pro-
duction, and rendered the heart less tolerant to ischemic
insult. This hyperglycemia-induced increase of IRI in
diabetes can be prevented by treatment with antioxi-
dants, N-Acetylcysteine and allopurinol, by activating
both the Akt and STAT3 involved signaling pathways
[12]. Activation of Akt may subsequently increase FoxO
phosphorylation, resulting its inactivation via nuclear
exclusion, and thus attenuate cardiac dysfunction caused
by hyperglycemia [36]. Similarly, in the present study,
there are reduced Akt phosphorylation at site Ser 473
and reduced STAT3 phosphorylation at site Ser727 in
diabetic heart relative to controls, accompanied by redu-
ced phosphorylation of glycogen synthase kinase (GSK)-
3β at site Ser 9. GSK-3β is a downstream target of RISK
signaling pathway, which is phosphorylated by Akt, and
plays important roles in necrosis and apoptosis of
cardiomyocytes [37]. Studies showed that activation
(phosphorylation) of Akt can phosphorylate (inactivate)
GSK-3β, which inactivates GSK-3β activity and confers
cardioprotection [38]. However, in diabetes, phosphoryl-
ation of Akt is reduced and the activity of GSK-3β is
increased, which may lead the heart damage to ischemic
insult [39]. In the present study, both Akt and GSK-3β
phosphorylation were reduced in diabetic heart both
before and after IRI, accompanied with increased apop-
totic cardiomyocytes. This indicates that impairment ofactivation of STAT3 and Akt may represent the funda-
mental mechanism responsible for the increased suscep-
tibility of the diabetic heart to IRI.
Conclusions
In summary, this study demonstrated that, in the early
stage of STZ-induced diabetes, rats displayed increased
myocardial oxidative stress and reduced antioxidant cap-
acity together with impaired Akt/GSK-3β and STAT3
activation, which rendered the diabetic heart more sensi-
tive to IRI. Moreover, increased myocardial injury in the
current diabetic rat model depends more on the duration
of ischemia but not that of reperfusion. Our findings
demonstrate that the diabetic heart, even at the early stage
of the disease, is more sensitive to IRI.
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